Damian Pharma

Executive Summary

Damian Pharma is a privately held Swiss biotechnology company based in Basel, founded in 2017 with a singular focus on developing first-of-a-kind therapies for aldosterone-dependent conditions. The company leverages its expertise in small molecule oncology to match distinct drug pharmacologies with well-characterized disease pathways, aiming to bring compassionate solutions to patients with high unmet medical needs. While specific pipeline details and financial information are not publicly disclosed, Damian Pharma's targeted approach and emphasis on aldosterone signaling suggest a niche but potentially impactful therapeutic strategy. As a private entity with no disclosed stage, valuation, or funding history, the company appears to be in early development, likely conducting preclinical or early clinical research. Its presence in Basel, a major biotech hub, provides access to talent and collaborations. The company's success hinges on advancing its lead candidate(s) through clinical validation and securing partnerships or funding to support development. Given the limited public information, the conviction score is moderate, reflecting uncertainty around pipeline progress and financial runway.